Navigation Links
Basis Extends Series B to more than $23 Million; Announces Mobile Veteran, Ethan Fassett, as VP of Product
Date:10/19/2013

SAN FRANCISCO, Oct. 8, 2013 /PRNewswire/ -- BASIS Science, Inc., (www.mybasis.com) the company behind Basis, the most advanced health tracker to improve fitness and sleep, today announced it has raised a further $11.75 million in Series B funding. The round included investments from Intel Capital, iNovia Capital, Dolby Family Trust, Stanford University and Peninsula-KCG. Existing investors Mayfield Fund, DCM and Norwest Venture Partners, also participated. This new investment represents the close of the Basis Series B financing, which now totals more than $23 million.

Basis also announced the expansion of its product team with the hire of Vice President of Product, Ethan Fassett, a veteran in mobile and platform product strategy. Most recently, Fassett was an entrepreneur in residence at Trinity Ventures. Previously, he served as senior vice president of product for GREE International, where he led development of its mobile social gaming platform in the US market. Prior to GREE, Ethan was executive producer for the San Francisco studio of the social gaming company Playdom, where he launched two titles and drove studio operations throughout their acquisition by Disney.

In his role, Ethan will leverage his extensive technology experience to drive Basis' product development, with a focus on the convergence of contextual data and wearable technology.  Building on Basis' biosensor approach to physiology and behavior change, Ethan and the team will continue to make the Basis system more intelligent through an enhanced understanding of user behavior patterns and intention, sensor-captured information and other data-based insights.

"We now capture billions of heart beats each week and our users remain more engaged with our system versus other options in the category," said Jef Holove, CEO, Basis. "With this new support, we'll be able to continue to build on our strong foundation and offer a great experience for many more people looking to build healthy habits."

According to IMS Research, the wearables market is poised to grow from 14 million devices shipped in 2011, to as many as 171 million units shipped by 2016, and given this explosive growth, there is understandably significant interest from investors.

"Wearable computing enables a data-driven approach to managing healthcare and fitness," said Arvind Sodhani, President of Intel Capital and Intel Executive Vice President. "By collecting heart rate, skin and ambient temperature data along with movement tracking, the Basis multi-sensor band opens up opportunities for data analytics driving deeper insights into health and personal behavior."

The Basis band is now available for purchase, priced at $199. For more information on buying the Basis band, purchasing accessories and free web service, and for the latest product updates, please visit: www.mybasis.com.

BASIS is a trademark of Basis Science, Inc. in the United States and other countries.

About Basis:
At Basis our mission is to help fit health into our busy lives. We designed our wrist-based health tracker and online personal dashboard to help you easily incorporate healthy habits into your daily routine. Basis leverages four types of advanced sensors in its lightweight, customizable design to calculate steps taken, calories burned and sleep quality, as well as physiological metrics like heart rate. We help you set new health goals and automatically adjust weekly targets based on your progress. Using this flexible approach you'll build healthy habits you can maintain for years. Basis Science, Inc. is backed by Mayfield Fund, Norwest Venture Partners and Doll Capital Management. For more information visit www.mybasis.com.


'/>"/>
SOURCE BASIS Science, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Researchers identify genetic basis of cardiac, craniofacial birth defects
2. International team discovers likely basis of birth defect causing premature skull closure in infants
3. Researchers discover genetic basis for eczema, new avenue to therapies
4. Molecular basis identified for tissue specific immune regulation in the eye and kidney
5. Dartmouth neuroscientist finds free will has neural basis
6. Unraveling the scientific basis of the infant feeding axiom breast is best
7. Notre Dame paper sheds light on genetic and physiological basis for metabolic diseases
8. Exclusive agreement to distribute Affinity Biosensors Archimedes system extends Malvern Instruments biopharma solutions
9. $1 million Kenan Trust Grant extends support of Scripps Florida education outreach
10. GEOLOGY returns to Naica Cave, Mexico, and extends its reach to Mercury
11. TGen, Scottsdale Healthcare study shows drug combination extends pancreatic cancer patient survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... Florida , March 29, 2016 ... the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased ... in ink used in a variety of writing instruments, ... Buyers of originally created collectibles from athletes on LegacyXChange ... forensic analysis of the DNA. Bill ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... Brooklyn, NY (PRWEB) , ... June 24, 2016 , ... ... 15mm, machines such as the Cary 5000 and the 6000i models are higher end ... height is the height of the spectrophotometer’s light beam from the bottom of the ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology: